SJ Corporation Regulatory Approval

SJ Corporation Acquisition Worth ₹7.56 Cr

SJ Corporation's subsidiary Fishfa Rubbers will invest up to Rs.7.56 Crore in Travia Consultancy, Singapore. Investment is via shares and convertible instruments, pending definitive agreements.

Value

₹7.56 Cr

SJ Corporation Dividend

SJ Corporation's board approved an interim dividend of ₹0.05 per equity share on October 24, 2026, with a record date of October 30, 2026. Payment is proposed by November 22, 2026.

SJ Corporation Q2 FY27 Results: Net Profit ₹2.2 Cr, Up 46.7% QoQ

SJ Corporation Ltd reported revenue from operations of ₹60.4 Cr and net profit of ₹2.2 Cr for Q2 FY27.

Key figure

Net profit ₹2.2 Cr

SJ Corporation Other Announcement

SJ Corporation Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.

SJ Corporation Board Meeting Date

SJ Corporation Ltd will hold a board meeting on October 24, 2026, to consider quarterly financial results and a potential interim dividend.

SJ Corporation Promoter Reclassification

SJ Corporation's board approved the promoter reclassification of two individuals to 'public category', along with a name change, office shift, and change in Company Secretary.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.